Cencora Investor Relations Strategy and Financial Data Analysis

Cencora's investor relations strategy is built on transparency and open communication. The company has a dedicated IR website that provides easy access to financial data, investor presentations, and SEC filings.

Cencora's financial data is regularly updated and made available to investors, with the most recent information available on the company's website. This commitment to transparency helps build trust with investors.

Cencora's investor relations team is responsible for maintaining the company's financial data and ensuring it is accurate and up-to-date.

As an investor, it's essential to understand the financial health of a company before making any investment decisions. Let's take a closer look at the financial data provided by Cencora in their investor relations.

Cencora's sales per share have been steadily increasing over the years, with a significant jump from $1,281.45 in 2023 to $1,467.71 in 2024.

The company's P/E ratio has also seen a notable increase, from 21.10 in 2023 to 29.87 in 2024, indicating a rise in investor confidence.

Here's a breakdown of Cencora's key financial metrics over the past few years:

Cencora's operating income has seen a significant increase, from $2,446.51 in 2023 to $3,040.13 in 2024, indicating a strong improvement in the company's profitability.

The company's equity ratio has also shown a notable improvement, increasing from 1.07% in 2023 to 1.17% in 2024.

Cencora's balance sheet total has increased by 7.26% from 2023 to 2024, indicating a steady growth in the company's assets.

However, the company's debt ratio has increased significantly, from 98.93% in 2023 to 98.83% in 2024, indicating a rise in the company's debt levels.

Overall, Cencora's financial data suggests a steady growth in sales and profitability, but also a rise in debt levels. As an investor, it's essential to carefully consider these factors before making any investment decisions.

Cencora's investor relations are built on a strong foundation of financial stability, with a steady stream of revenue generated through service fees and percentage fees tied to the value of distributed goods. The company's vast and exponentially growing distribution channels are a key driver of this revenue growth.

Cencora's profitability is further supported by its integrated service offerings, including consulting, analytics, and supply chain management solutions. These services provide additional avenues of income by addressing the strategic needs of the company's clientele.

The company's financial performance is expected to continue growing, with revenue estimates ranging from $322,491 USD in 2025 to $450,042 USD in 2029.

Cencora Inc is a pivotal player in the healthcare landscape, with a vast and exponentially growing distribution network that earns revenue through service fees and percentage fees tied to the value of distributed goods.

The company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora to serve as a conduit for drug distribution and a trusted advisor in the healthcare sphere.

Cencora's profitability is evident in its sales per share, which has consistently increased over the years, reaching $1,467.71 in 2024. The company's ability to adapt and innovate within rigid regulatory frameworks has enabled it to thrive in a complex industry.

Here's a breakdown of Cencora's sales per share over the years:

Cencora's dividend yield has also been steadily increasing, reaching 0.91% in 2024. The company has consistently paid dividends to its shareholders, with a history of stable dividend payments dating back to 2001.

The company's ability to adapt and innovate within rigid regulatory frameworks has enabled it to thrive in a complex industry.

Cencora has a history of releasing earnings reports, with the most recent one being $2.500 USD in Q1 2025. The company also hosts annual general meetings, with the most recent one being held on 02/05/2025.

Earnings reports have been a regular occurrence for Cencora, with some notable releases including $2.420 USD in Q3 2024 and $2.090 USD in Q2 2024. These reports provide valuable insights into the company's financial performance.

Here are some key dates to note for Cencora's past events:

Analyst opinions play a significant role in shaping investor sentiment and influencing stock prices. Analysts have been actively providing their estimates for Cencora's revenue and earnings.

A total of 14 analysts have provided their estimates for Cencora's next year earnings, with an average estimate of $16.83 USD. This is a significant increase from the previous year's estimate of $7.60 USD.

The number of analysts providing revenue estimates for Cencora has ranged from 12 to 14, with an average estimate of $345,046 USD for the next year. This is a notable increase from the previous year's estimate of $293,959 USD.

Here's a summary of analyst estimates for Cencora's next year earnings and revenue:

Analysts have been actively monitoring Cencora's financial performance and providing their estimates for future growth. Their opinions can have a significant impact on investor decisions.

Cencora Management is made up of a diverse group of experienced leaders. Lazarus Krikorian serves as the Chief Accounting Officer & Senior Vice President.

The company has a strong financial leadership team, with James Francis Cleary as the Chief Financial Officer & Executive VP. Silvana Battaglia is the Chief Human Resources Officer & Executive VP.

In addition to financial and human resources leadership, the company also has a strong compliance team, led by Jennifer E. Dubas as the Chief Compliance Officer & Senior Vice President. Elizabeth S. Campbell is the Chief Legal Officer & Executive Vice President.

The company's strategy is led by François Mandeville, who serves as the Chief Strategy Officer & Executive VP. Steven H. Collis is the Executive Chairman.

The company also has a strong data and information team, led by Pawan Verma as the Executive VP, Chief Data & Information Officer.

Here is a list of the company's management team:

Cencora Inc. is a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe.

The company's vast and exponentially growing distribution channels are a key factor in its profitability, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods.

Cencora's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele.

The company's dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused.

Cencora's revenue is projected to reach $450,042 in 2029, with an estimated growth rate of 11.4% from 2028.

Here's a breakdown of Cencora's revenue estimates for the next few years:

Cencora's dividend yield is expected to be 0.94% in 2026, with a projected dividend of $2.27 per share.

The company's earnings per share (EPS) is estimated to be $16.82 in 2026, with a projected growth rate of 9.5% from 2025.

Cencora's net profit is projected to reach $4,204 in 2029, with an estimated growth rate of 7.3% from 2028.

The company's free cash flow is projected to reach $4,266 in 2029, with an estimated growth rate of 8.1% from 2028.

Cencora's net debt is expected to be -$1,816 in 2026, with a projected decrease in net debt by 373% from 2025.

The company's research and development expenses are not disclosed in the provided data.

Cencora's capital expenditure is projected to reach $728 in 2029, with an estimated growth rate of 8.1% from 2028.

The company's selling, general, and administrative expenses are projected to reach $7,760 in 2028, with an estimated growth rate of 12.8% from 2027.

Cencora's shareholder's equity is projected to reach $1,419 in 2029, with an estimated decrease of 75.3% from 2028.

The company's total assets are projected to reach $88,824 in 2029, with an estimated growth rate of 1.2% from 2028.

Cencora's earnings estimates are provided by 14 analysts, with an average estimate of $16.82 per share in 2026.

The company's revenue estimates are provided by 13 analysts, with an average estimate of $345,046 in 2026.

Cencora's average estimate for earnings per share has increased by 39.5% from 2025 to 2026.

The company's average estimate for revenue has increased by 8.5% from 2025 to 2026.

Stocks are a crucial part of any investment portfolio, and understanding their value is essential for making informed decisions. Cencora Inc, for example, is currently trading at $242.03 USD on the NYSE, with a -0.25% change.

Market price and fair value are two different things, with fair value showing the value of a stock based on a company's actual financials. Franklin Covey Co has a fair value of $34.67 USD, while Mohawk Industries Inc is trading at $119.495 USD.

Economic Moat is a concept that describes a company's durable competitive advantage, and companies like Johnson & Johnson have a strong economic moat. Johnson & Johnson is trading at $155.14 USD on the NYSE, with a -0.65% change.

Companies with exceptional profitability and efficient operations, such as Arista Networks Inc, have a strong track record of success. Arista Networks Inc is trading at $109.3056 USD on the NYSE, with a 2.28% change.

Here are some companies with the lowest probability of bankruptcy, based on their financial health:

These companies are frequently analyzed and tracked by Alpha Spread users, including Johnson & Johnson, Berkshire Hathaway Inc, and Mastercard Inc.

Cencora investor relations is all about understanding the value of a company beyond its market price. The fair value of a stock, for instance, is determined by analyzing a company's financials such as cash balance, revenue, and operating margin.

Armed with this knowledge, investors can make more informed decisions about their investments. For example, a company like Franklin Covey Co (NYSE:FC) has a fair value of $34.67 USD, which is lower than its current market price.

Fair value is a crucial concept in evaluating the attractiveness of investments. It's not just about what others are willing to pay, but also about the company's actual financials. For instance, Cencora Inc (NYSE:COR) has a fair value of $242.03 USD, which is slightly lower than its current market price.

To give you a better idea, here are some stocks with their fair values and market prices:

By understanding the fair value of a company, investors can make more informed decisions about their investments.